THE ALLFTD TEAM

ALLFTD Principal Investigators

Dr. Bradley Boeve

Bradley F. Boeve, M.D., is a consultant in the Department of Neurology and Center for Sleep Medicine at Mayo Clinic in Rochester, Minnesota. Dr. Boeve also serves as chair of the Division of Behavioral Neurology and is co-director of the Clinical Core of Mayo’s Alzheimer’s Disease Research Center. He joined the staff of Mayo Clinic in 1997 and holds the academic rank of professor of neurology, Mayo Clinic College of Medicine and Science. Dr. Boeve is recognized with the distinction of the Little Family Foundation Professorship in Lewy Body Dementia.

Dr. Boeve received his M.D. from the University of Florida. He further trained at Mayo Clinic School of Graduate Medical Education where he completed internship in internal medicine, residency in neurology, and fellowships in both behavioral neurology and sleep medicine.

Dr. Boeve’s clinical and research interests include normal aging, mild cognitive impairment, Alzheimer’s disease as well as the non-Alzheimer’s degenerative dementias such as dementia with Lewy bodies, frontotemporal dementia, primary progressive aphasia, corticobasal degeneration, progressive supranuclear palsy and posterior cortical atrophy. He also has interests in the neurologically based sleep disorders such as REM sleep behavior disorder, narcolepsy and restless legs syndrome.

Dr. Adam Boxer

Adam L. Boxer, MD, PhD, is Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF). He directs UCSF’s Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center. Dr. Boxer’s research is focused on developing new treatments and biomarkers for neurodegenerative diseases, particularly those involving tau and TDP-43.

Dr. Boxer received his medical and doctorate degrees as part of the NIH-funded Medical Scientist Training Program at New York University Medical Center. He completed an internship in Internal Medicine at California Pacific Medical Center, a residency in Neurology at Stanford University Medical Center, followed by a fellowship in behavioral neurology at UCSF.

He is also the principal investigator (PI) of the Four Repeat Tauopathy Neuroimaging Initiative (4RTNI), a multicenter, longitudinal tau PET and biomarker study focused on PSP and CBD. He has been the PI for a variety of multicenter, randomized, placebo controlled clinical trials in FTLD spectrum disorders, including memantine for FTLD, davunetide for PSP, TPI-287 for primary and secondary tauopathies, and salsalate for PSP. In the past he has led a variety of clinical trials in FTD and PSP including a US multicenter, randomized, placebo-controlled, clinical trial of a therapeutic agent for frontotemporal dementia (memantine/Namenda®) and an international, phase 2/3, randomized, placebo-controlled trial of the microtubule stabilizing agent, davunetide (NAP, Al-108), for PSP. He is lead principle investigator for an international Phase 2 clinical trial of the tau monoclonal antibody, BIIB092, for PSP. He also leads the FTD Treatment Study Group (FTSG), a group looking to speed the development of new therapies for FTD.

Dr. Howard Rosen

Howie Rosen completed a combined BA/MD program at Boston University in 1989, a residency in Internal Medicine at Albert Einstein College of Medicine in 1992, and a Neurology residency at UCSF in 1996. He then trained in cognitive neuroscience and brain imaging at Washington University in St. Louis and returned to UCSF to join the faculty at the UCSF Memory and Aging Center in 1999. He is an investigator on multiple federal and state-funded research grants and serves as director of the California State Alzheimer’s Disease Center at UCSF, associate director of UCSF’s federally funded Alzheimer’s Disease Research Center, director of UCSF’s Behavioral Neurology Training Program, and director of Curriculum for the Global Brain Health Institute.

Rosen’s research involves the use of brain imaging and novel assessments of socioemotional functioning to provide objective and sensitive measurements of brain changes that occur in neurodegenerative illnesses. These efforts are conducted through multicenter projects that enroll patients suffering from these disorders as well as those at risk because of genetics or other factors.

Rosen directs the California Alzheimer’s Disease Center (CADC) at UCSF, which has offered comprehensive multidisciplinary assessment and care for hundreds of patients with cognitive and behavioral difficulties and coordinates with other CADCs to improve dementia care throughout California. As director of the Imaging Core at the UCSF Memory and Aging Center, he supports the work of many other investigators and collaborators interested in brain imaging. He also supervises unique programs that reach out to medically undeserved communities in the Bay Area, in particular Chinese Americans. All of these efforts are designed to overcome scientific and cultural barriers that impede the early and accurate diagnosis of neurodegenerative diseases and prepare us for an era when these diseases are treated before they can cause serious impacts on daily living.

Most recently, Rosen became director of Curriculum for GBHI. He also serves as director of the Outreach and Education Core for UCSF’s Alzheimer’s disease research center and director of UCSF’s Behavioral Neurology Training Program. Through these initiatives, he designs and supervises programs that prepare the next generation of dedicated professionals to carry on with this work until the threat posed by dementia is eradicated throughout the world.

Sometimes we’re goofy :)

ALLFTD kickoff! ALLFTD Investigators’ Meeting 2019.